Table 6.
No. | Change on the company base case |
---|---|
1 | Removal of programming errors (half cycle correction and docetaxel price calculations) |
2 | Weight/body surface area and treatment-specific hospital length of stay of patients based on region 1, not all patients in the trials |
3 | Correction of double counting for hospitalizations due to adverse events |